Profile cover photo
Profile photo
OIS: Ophthalmology Innovation & Investment
529 followers -
OIS facilitates meaningful interactions and partnerships between investors, entrepreneurs, industry executives, and physicians who drive ophthalmic innovation
OIS facilitates meaningful interactions and partnerships between investors, entrepreneurs, industry executives, and physicians who drive ophthalmic innovation

529 followers
About
Posts

Post has attachment
In August, the OIS Index lost ground relative to its benchmark indices, declining 1.5% after a similar 1.6% decline in July. Read this OIS article to learn more:
Add a comment...

Post has attachment
What could the acquisition of TearScience and Kala Pharmaceuticals mean for the broader M&A and IPO activity? We ask Andrew Gitkin of West Coast biotechnology investment banking at Piper Jaffray.
Add a comment...

Post has attachment
What Was the Most Difficult Part of Successfully Transitioning to CMO? We Ask B&L’s Cal Robert.
Add a comment...

Post has attachment
CEO of ProFarma lays out the company’s plan to improve the delivery and effective life of drugs that strengthen neuroprotectiveness in retina ganglion cells.
Add a comment...

Post has attachment
Graybug Vision is moving ahead with trial design for a single ascending-dose study of its candidate GB-102 for intravitreal injection in retinal disease. Learn more:
Add a comment...

Post has attachment
Charles Semba, MD, is becoming known as a force in the development of new ophthalmology treatments. Listen to this OIS Podcast to learn more:
Add a comment...

Post has attachment
If you would like to attend the Nov 9th OIS@AAO, we are offering a Group Rate when you register 3 or more individuals from the same company. Learn more today:
Add a comment...

Post has attachment
What qualities do funders want to see in founders? Learn more:
Add a comment...

Post has attachment
Ashley McEvoy , Company Group Chairman for Johnson & Johnson Vision, explains where TearScience will fit into J&J if the deal is completed and what the global giant’s plans for additional Dry Eye treatments may be.
Add a comment...

Post has attachment
OIS Index reports major ophthalmic pipeline developments in July. Learn more:
Add a comment...
Wait while more posts are being loaded